Results 1 to 10 of about 169 (91)

Effectiveness and safety of levilimab in combination with methotrexate in treatment of patients with active rheumatoid arthritis resistant to methotrexate monotherapy (double-blinded randomized placebo controlled phase III clinical study SOLAR)

Современная ревматология, 2021
Levilimab is anti-interleukin-6 receptor (IL6R) monoclonal antibody. The article presents data obtained during 24 weeks of the SOLAR phase III study.Objective: to confirm efficacy and safety of levilimab in combination with methotrexate (MTX) in patients
V. I. Mazurov, M. A. Korolev, A. M. Prystrom, E. V. Kunder, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Kretchikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, Yu. N. Linkova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, A. V. Eremeeva, A. A. Lutckii   +25 more
doaj   +3 more sources

Efficiency of Levilimab in patients with moderate and severe COVID-19

Фармакоэкономика, 2023
Objective: evaluation of the clinical and economic efficiency of using Levilimab in the treatment of moderate and severe COVID-19 based on real world data (RWD).Material and methods.
Yu. M. Gomon, V. V. Strizheletsky, I. G. Ivanov, Yu. E. Balykina, M. V. Ermolyev, A.  S. Kolbin, M. V. Livshits, T.  A. Usmanova, A. M. Fakhrutdinova, Yu. S.  Konstantinova, A. P. Gubanov   +10 more
doaj   +2 more sources

Levilimab and baricitinib prescribing experience in outpatient COVID-19 patients’ treatment

Терапевтический архив, 2022
Aim. To study the effect of levilimab or baricitinib in combination with standard therapy (ST) on the incidence of severe viral pneumonia associated with a new coronavirus infection COVID-19. Materials and methods.
Alexey I. Khripun, Andrey V. Starshinin, Yulia O. Antipova, Mariana A. Lysenko, Yulia V. Urozhaeva, Olga F. Gavrilenko, Natalya A. Rusantsova, Andrei A. Tyazhelnikov, Elena Yu. Tikhonovskaya, Natalia V. Okolot, Maria V. Sokolova, Daria S. Fomina, Elena N. Simonova, Tatiana S. Kruglova, Anton A. Chernov, Alena I. Zagrebneva   +15 more
doaj   +3 more sources

Efficacy and safety of levilimab in combination with methotrexate in patients with active rheumatoid arthritis: 56-week results of phase III randomized double-blind placebo-controlled trial SOLAR

Научно-практическая ревматология, 2023
Background. Previously, 24-week results of phase III double-blind, placebo-controlled randomized clinical study (SOLAR) of levilimab in subjects with active rheumatoid arthritis (RA) proved a superiority of levilimab over placebo.
V. I. Mazurov, A. M. Lila, M. A. Korolev, A. M. Prystrom, A. V. Kundzer, N. F. Soroka, A. A. Kastanayan, T. V. Povarova, T. V. Plaksina, O. V. Antipova, D. G. Krechikova, S. A. Smakotina, O. A. Tciupa, E. V. Puntus, T. A. Raskina, L. N. Shilova, T. V. Kropotina, O. B. Nesmeyanova, T. A. Popova, I. B. Vinogradova, E. A. Dokukina, A. V. Plotnikova, P. S. Pukhtinskaia, A. V. Zinkina-Orikhan, Yu. N. Linkova, A. V. Eremeeva, A. A. Lutckii, E. L. Nasonov   +27 more
doaj   +3 more sources

Living in LALA land? Forty years of attenuating Fc effector functions. [PDF]

Immunol Rev
Summary The Fc region of antibodies is vital for most of their physiological functions, many of which are engaged through binding to a range of Fc receptors. However, these same interactions are not always helpful or wanted when therapeutic antibodies are directed against self‐antigens, and can sometimes cause catastrophic adverse reactions.
Hale G.
europepmc   +2 more sources

Antibodies to watch in 2021 [PDF]

mAbs, 2021
In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody therapeutics development that occurred in 2020 and forecast events that might occur in 2021.
Hélène Kaplon, Janice M. Reichert
doaj   +2 more sources

Interleukin 6 receptor inhibitors in the treatment of rheumatoid arthritis during the COVID-19 pandemic, Moscow experience

Современная ревматология, 2022
Objective: to confirm the efficacy and safety of levilimab in patients with rheumatoid arthritis (RA) switched from other interleukin 6 receptor inhibitors (iIL6R) for non-medical reasons.Patients and methods.
A. I. Zagrebneva, E. N. Simonova, T. V. Mezenova, N. B. Burmistrova, Yu. A. Gavrikova, Yu. A. Gavrikova, E. O. Morozova, Zh. M. Kodzeva, K. S. Sapogina   +8 more
doaj   +1 more source

Levilimab clinical efficacy for interleukin-6 receptor inhibition in COVID-19 and its potential for treating cytokine release syndrome of other aetiologies

Биопрепараты: Профилактика, диагностика, лечение, 2022
The COVID-19 mortality is associated with an increase in interleukin-6 (IL-6) levels. Levilimab is an anti–IL-6 receptor antibody with proven clinical efficacy in patients with severe COVID-19.The aim of the study was to assess the association of COVID ...
N. V. Lomakin, B. A. Bakirov, G. H. Musaev, V. V. Popov, E. A. Smolyarchuk, Yu. N. Linkova, D. V. Bogdan, A. V. Eremeeva, P. S. Pukhtinskaia, M. A. Morozova, A. V. Zinkina-Orikhan, A. A. Lutckii   +11 more
doaj   +1 more source

Signaling pathways in macrophages: molecular mechanisms and therapeutic targets

MedComm, Volume 4, Issue 5, October 2023., 2023
In this review, the authors introduce the research advances related to macrophage signaling pathways by first providing an overview of the basic physiology of macrophages and expound on the regulatory pathways within them. Then, the pathogenic effect of macrophages and the therapeutic strategies targeting macrophage signaling pathways are addressed in ...
Ming Li, Mengjie Wang, Yuanjia Wen, Hongfei Zhang, Guang‐Nian Zhao, Qinglei Gao   +5 more
wiley   +1 more source

Inflammatory cytokines as mediators of retinal endothelial barrier dysfunction in non‐infectious uveitis

Clinical &Translational Immunology, Volume 12, Issue 12, 2023., 2023
Non‐infectious uveitis has a range of ocular and systemic autoimmune and autoinflammatory causes. When the retina is involved, blood‐retinal barrier breakdown can lead to vision loss. Specific cytokines stand out as promoting intraocular inflammation. This article reviews the involvement of inflammatory cytokines – including tumour necrosis factor (TNF)
Lisia Barros Ferreira, Keryn A Williams, Giles Best, Cameron D Haydinger, Justine R Smith   +4 more
wiley   +1 more source